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(From the Department of Medicine and Microbiology, University of Washington, Seattle,
Washington 98195)
Polymorphonuclear leukocytes (PMN) employ a system comprised of myelo-
peroxidase (MPO), H20 2, and an oxidizable halide cofactor to kill a variety of
microorganisms (for reviews see 1, 2) . After particle ingestion, MPO is released
into the phagocytic vacuole and H20 2 is produced in association with the
postphagocytic metabolic burst . BothMPO (3, 4) and H202 (5) are also released
into the extracellular fluid during phagocytosis . While the intravacuolar role of
the MPO system is well established (1, 2), no extracellular biologic activity of
this system other than iodination of nonspecific proteins (1, 6) has been
demonstrated . The killing of mammalian tumor cells by the peroxidase system
employing isolated components has recently been described (7-9) . The current
report documents a cytotoxic effect of intact human PMN on neoplastic cells
and provides evidence for the involvement of the peroxidase system in mediating
this activity .
Materials and Methods
Target Cells .
￿
An ascitic Moloney virus-induced lymphoma (LSTRA) (9) maintained by intraperi-
toneal passage in BALB/c mice was used as the target cell source . Cells were harvested from ascites
fluid as previously described (9) . All incubations were performed in a 37*C water bath shaker
oscillating 60 times/min .
"Cr Release .
￿
LSTRA cells were labeled with [6'Cr]chromate, washed, and suspended in 0.1 M
sodium phosphate buffer, pH 7.0 (PB) and "Cr-release assays performed as previously described (9) .
Briefly, labeled LSTRA cells were incubated for 2 h with the components of the cytotoxicity system
(see table legend), andthe mean release of "Cr in duplicate samples was expressed as a percent of
maximum releasable activity .
Oncogenicity . LSTRA cells were incubated at 37°C for 2 h with the components of the
cytotoxicity system before injection into the peritoneal cavity of BALB/c mice for the determination
of oncogenicity as previously described (9) .
Leukocyte Preparation .
￿
The Ficoll-Hypaque technique (10) was employed to isolate PMN from
the blood of healthy adult volunteers, one male with hereditary MPO deficiency (11), two brothers
with leukocyte glucose-6-phosphate dehydrogenase (G6PD) deficiency (12), and four males with
chronic granulomatous disease of childhood (CGD) . After hypotonic lysis of contaminating erythro-
cytes, the granulocyte pellet was washed twice in 0.1 MPB and suspended in 0.1 M PB at 5 x 10 6
PMN/ml . These suspensions averaged 95.2% PMN in normal subjects and 94.4% PMN in patients .
Special Materials.
￿
Sodium ["Cr]chromate (200-500 pCi/fag Cr) was obtained from NewEngland
Nuclear, Boston, Mass., glucose oxidase (type-V, 200 U/mg) from Sigma Chemical Co ., St . Louis,
Mo ., and catalase (beef liver, crystalline, 54,500 U/mg) from Worthington Biochemical Corp ., Free-
* This work was supported in part by grants A107763 and HD02266 from the U. S . Public Health
Service .
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hold,N. J. MPO prepared from canine PMN by the method of Agner through the endof step six (13)
was assayed by the o-dianisidine method (14) ; 1 U utilizes 1 umol of substrate/min at 25°C (15) .
Zymosan(Nutritional Biochemical Corp ., Cleveland, Ohio) washomogenized, incubated for 20 min at
37°C in either fresh frozen (-70°C) human AB serum (preopsonized zymosan) or modified Hanks'
solution (9) (nonopsonized zymosan), washed, andsuspended in water at 10 mg/ml.
Results
PMN-Zymosan-Halide Cytotoxicity System .
￿
Table I demonstrates the cyto-
toxic effect of a system comprised ofPMN, preopsonized zymosan, and a halide .
Significant "Cr release above control (P < 0.001) was observed using either 0.1
M chloride or 10 -4M iodide as the halide or using a combination of both halides
TABLE I
PMN-Zymosan-Halide Cytotoxicity System
"Crrelease
The complete reaction mixture contained 0.03Msodium phosphate buffer pH 7.0, 1.5 x 10- 'M
KH,P0,, 1.5 x 10- 'MMgSO 10 5 LSTRA cells, and thesupplements indicated below as follows :
PMN, 2.5 x 10 5 ; zymosan (ZYM), 0.1 mg (preopsonized except as indicated) ; chloride and iodide
as the sodium salts in theconcentrations indicated ; azide and cyanide as thesodium salts at 10- `
M; and catalase, 1,400U. In tubes containing either no NaCl or 4 x 10- 'M NaCl,Na,S0 0.067M
or 0.04 M, respectively, was added to maintain isosmolarity . Total volwas 0.5 ml . PMN or catalase
were preheated at 100°C for 15 min where indicated .
*Mean tSE (number of experiments) .
$ Significantly increased above control, P < 0.001 ; all others NS (t test) .
at concentrations at which either one alone showed only minimal activity . Under
these latter conditions the combined effect of chloride and iodide was greater
than additive . Cytotoxicity was abolished by deletion of each component of the
system, by pretreating the PMN with heat, homogenization or sonication, or by
the use of nonopsonized zymosan. These experiments all employed a ratio of
effector to target cells of 2.5:1 . A cytotoxic effect was present at a ratio of 1 .25:1
but was not detectable at 0 .5:1 .
Supplements
Chloride (10-'M) Iodide (10-' M)
Chloride (4 x 10-xM)
+ iodide (10--5 M)
Control (nosupplements) 24.6 t0.7 (28)* 24.6 t 0.7 (28)* 24 .6 t 0.7 (28)*
PMN+ZYM+ halide(s) 38.8 t 1.1 (38)$ 40.4 t 1.1 (30)$ 44 .5 t 0.9 (31)$
PMNomitted 19.4 t 1.2 (9) 21 .4 t 0 .8 (6) 22 .0 t 2.4 (4)
ZYMomitted 26 .5 t 1.5 (10) 23 .9 t 1.1 (7) 26 .0 t 1 .3 (5)
Chloride omitted 18 .8 t 1 .1(11) - 27 .2 t 1 .2 (7)
Iodide omitted - 18 .8 t 1 .1 (11) 27 .0 t 1 .1 (7)
PMN heated 20 .0 t 0.5 (2) 19.6(l) 21 .5(t)
PMN homogenized 22 .1 t 0.8 (2) 20.8(l) 21.3(l)
PMN sonicated 18.2(1) 18.9(l) 26.5(l)
ZYM nonopsonized 24 .9 t 1 .0 (2) 22.5 f 0.4 (2) 24.2 t 1.2 (2)
Azide added 24 .2 t 1.4 (6) 23.2 t 0.9 (4) 22.0 t2.3 (3)
Cyanideadded 21.0 t 0.6 (4) 19.3 f0.9 (3) 18 .1 t 1.2 (3)
Catalase added 22 .3 t 1 .6 (5) 22.3 t 1.0 (5) 19.5 t0.2 (2)
Heated catalase added 32.0 t 1 .6 (4)$ 41.6 t 1.6 (5)$ 36.8 t2.3 (2)$1444
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A cyctotoxic effect ofPMN was also demonstrated by loss of oncogenicity of
LSTRA target cells for mice . Nearly all animals (22 of 24) receiving 10 5 control
LSTRA cells exposed to the buffer system alone developed tumors and died . In
contrast, only 6 of 24 mice receiving cells exposed to the complete cytotoxicity
system (PMN, zymosan, 0.04M chloride, and 10 -5 M iodide as in Table I) died
with tumors (P < 0.05, chi-square test) . Omission of PMN, zymosan, or both
halides resulted in tumors and death in six of six, six of six, and five of six
animals, respectively .
Involvement of the Peroxidase System . The mechanism of the cytotoxic
effect of phagocytosing PMN was initially investigated with the use of specific
inhibitors (Table 1) . Cytotoxicity was abolished by the heme enzyme inhibitors,
azide and cyanide . Catalase caused similar inhibition, an effect which was largely
reversed by preheating the enzyme . Since these studies suggested involvement of
MPO and H20 2 , experiments were performed employing PMN from patients
with leukocytic defects including a patient with hereditary MPO deficiency and
six patients with defective H 20 2 production (leukocyte G6PD deficiency and
CGD) . No significant release of "Cr above controls was observed when PMN
from any of these patients were substituted for normal cells (Fig . 1) . Attempts
were then made to restore cytotoxic activity by adding purified MPO, reagent
H 202or a peroxide generating enzyme system (glucose and glucose oxidase) (Fig .
1, inset) . MPO-deficient PMN had a potent cytotoxic effect in the presence of
added MPO (p < 0.001, t test) but remained without activity when H20 2 or
glucose oxidase was added. In contrast, PMN from CGD patients remained in-
active when MPO was added, but significant cytotoxic activity was restored by
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￿
Cytotoxicity system usingPMN from patients with leukocytic defects . The reaction
mixtures were as described for thecomplete PMN-zymosan-halide systems in Table 1 . Halide
concentrations were as follows : chloride system, 0.1M NaCl ; iodide system, 10'M Nal; and
chloride plus iodide system, 0.04 MNaCl and 10-5M Nal. For ease of interpretation, control
values have been subtracted from experimental values and results expressed as mean percent
release of "Cr above controls (t SE). The diagnosis, patients' initials, and number of
observations in parentheses are indicated on the abscissa . The data in the inset represent the
means of nine studies with normal PMN, three studies with PMN from the patient with
hereditary MPO deficiency, and a total of nine studies with PMNfrom the four CGD patients.
Forthese experiments the complete reaction mixture was as described above for the chloride
plus iodide system with the supplements as follows : MPO, 16 mU ; H,O,, 5 x 10-5M; and
glucose oxidase, 0.14U. When glucose oxidase was used, 0.01M D-glucose was also added .
zo
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eitherH202 (p< 0.01) or the glucose oxidase system (p < 0.001), the latter being
more effective . This restoration of activity is consistent with reports ofnormal or
increased H202 production by MPO-deficient PMN (16) and normal secretion of
MPO in CGD leukocytes (3, 17).
Discussion
These studies demonstrate the ability of human PMN to act as effector cells
against mammalian tumor cells in vitro using a relatively low ratio of effector to
target cells and two cytotoxicity assays : S 1Cr release and loss of oncogenicity .
Cytotoxicity depends on the presence of intact PMN, phagocytosable particles,
and a halide cofactor . Studies employing inhibitors and leukocytes from patients
with neutrophil dysfunction syndromes clearly implicate MPO and H20 2 in
mediating this cytotoxic effect . A mechanism involving the reaction of secreted
MPO andH 202 with extracellular halides to form a cytotoxic system is proposed .
Since the blood monocyte also containsMPOand formsH202 during phagocyto-
sis (for review see 18), the MPO-mediated cytotoxicity system may also be
operative with this cell type .
While the data presented point out the cytotoxic potential of PMN via the
MPO-H202-halide system, the effects observed are not target cell specific . In
particular there is currently no evidence for increased susceptibility of tumor
cells to peroxidase-mediated damage and toxic effects of the isolated peroxidase
system on normal mammalian cells have been clearly demonstrated (7,15,19) .
Neutrophil-mediated cytotoxicity could acquire target cell specificity through
the participation of humoral or cellular immune responses to tumor antigens .
Immunologically directed neutrophil accumulation might be expected to result
from the release of chemotactic lymphokines or the interaction of neoplastic cells
and tumor-specific antibody with associated formation of complement-derived
chemotactic agents . Attachment of antibody molecules to the tumor cell surface
would also provide a mechanism for immunologically specific release of peroxi-
dase system components. While particle ingestion served as the stimulus for
MPO and H 202 release in the current study, secretion of enzymes (4, 20) includ-
ingMPO (4) and metabolic stimulation (17, 21) also occur when neutrophils come
in contact with antigen-antibody complexes on a nonphagocytosable membrane
surface . Evidence has been presented for in vivo attachment of immunoglobulins
to the surface oftumor cells (22) and a report of in vitro killing of antibody-coated
malignant cells by human neutrophils has recently appeared (23) . The demon-
stration of peroxidase-mediated cytotoxicity for mammalian tumor cells using
both cell-free systems (7,9) andintact humanPMN raises the possibility that the
neutrophil is involved via the peroxidase system in the host defense against neo-
plastic disease.
Summary
A cytotoxic effect of human neutrophils on mammalian tumor cells is
demonstrated . Cytotoxicity depends on the presence of intact neutrophils,
phagocytosable particles, and a halide cofactor and is inhibited by azide,
cyanide, and catalase . Neutrophils from patients with myeloperoxidase (MPO)1446
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deficiency or defective H202 production are not cytotoxic, but activity is restored
by addition of purified MPO or H202 respectively . The findings support a
mechanism involving the phagocytosis-induced extracellular release ofMPO and
H202 and their reaction with a halide cofactor to damage the target cells .
The authors thank Ms . Coralie Baker and Ms . Susan Geisler for excellent tech-
nical assistance .
Received for publication 24 February 1975 .
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